News
‘I was hooked’- Jennifer Aniston joins functional fitness brand Pvolve
The actress will work on key areas of the business including product development, marketing and programming strategy
Actress Jennifer Aniston has announced she will join the functional fitness brand Pvolve after she fell in love with its low-impact workouts.
Pvolve, a platform that pairs low-impact functional movement with resistance-based equipment, claims to help women target “hard-to-hit” muscles and build strength without the drain of traditional workouts.
Because the method integrates all ranges of motion – side-to-side, front-to-back, and rotational – the company says it activates major and surrounding muscle groups to enhance the physique and improve strength, mobility, and stability.
Aniston fell in love with the brand when she was introduced to the platform in 2021.
“In 2021 I had a really bad back injury, and I don’t feel like myself when I’m not able to work out,” the actress said.
“I have a friend who had already been doing Pvolve and not only did I notice her complete transformation, physically and in her energy level, but she also explained that Pvolve’s functional fitness method respects where your body is at and allows you to work around your current limitations, so you don’t have to sit on the bench and wait for full recovery.
“I ordered the equipment and started streaming the workouts at home and instantly fell in love with the programme and its results. Then, once I was back to full strength, I saw how broad the range of workout options are, and I was hooked.
“It’s completely different from anything I’d tried before and that’s what made me want to get involved with the company,” she added.
“I especially love movements that work my core and arms, and the P.band, P.ball and gliders are really great for that, plus they’re easy to pack when I travel.”
Rachel Katzman, founder of Pvolve, said she was blown away when she found out Aniston was a secret streamer.
“The fact that someone so advanced in her fitness journey and with access to a world of options, fell in love with the method after experiencing its benefits, is a dream come true,” she said.
Over the last year, in addition to streaming classes from her home, Aniston has added in-person training with Pvolve director of training and head trainer, Dani Coleman.
As part of her collaboration with Pvolve, the actress will work on key areas of the business such as product development, marketing, and programming strategy, while also starring in future ad campaigns.
To get started with the Pvolve method, women can purchase the brand’s signature bundle which includes three pieces of equipment and one month of free streaming. Those looking to go all-in on the complete experience can buy the total transformation bundle which features 13 pieces of strength training and restorative equipment and unlocks one year of free streaming.
The brand also has physical studio locations, including franchises, in New York, Chicago, Los Angeles and San Diego, with more franchise studios opening this year across the US and Canada.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






